Compare · MANE vs NVO
MANE vs NVO
Side-by-side comparison of Veradermics Incorporated (MANE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MANE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 50.4x MANE ($4.28B).
- MANE has been more active in the news (14 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 6 for MANE).
- Company
- Veradermics Incorporated
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $4.28B
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2026
- News (4w)
- 14
- 9
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MANE
- Amendment: SEC Form SCHEDULE 13D/A filed by Veradermics Incorporated
- Director Montanova Capital, Llc sold $80,437,500 worth of shares (750,000 units at $107.25) and converted options into 300,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Hollander David
- Chief Technical Officer Durso Timothy August exercised 3,452 shares at a strike of $12.19 and sold $4,690,005 worth of shares (43,500 units at $107.82), decreasing direct ownership by 34% to 78,142 units (SEC Form 4)
- Chief Executive Officer Waldman Reid Alexander sold $7,280,713 worth of shares (67,500 units at $107.86) and exercised 3,452 shares at a strike of $12.19, decreasing direct ownership by 27% to 170,824 units (SEC Form 4)
- SEC Form EFFECT filed by Veradermics Incorporated
- Amendment: SEC Form 144/A filed by Veradermics Incorporated
- Director Childs John W sold $10,711,700 worth of shares (100,000 units at $107.12) (SEC Form 4)
- SEC Form 424B3 filed by Veradermics Incorporated
- SEC Form 10-Q filed by Veradermics Incorporated
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S